S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
My No. 1 dividend stock for a LIFETIME of income. (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
My No. 1 dividend stock for a LIFETIME of income. (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
My No. 1 dividend stock for a LIFETIME of income. (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
My No. 1 dividend stock for a LIFETIME of income. (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
NASDAQ:BVXV

BiondVax Pharmaceuticals - BVXV Stock Forecast, Price & News

$2.11
-0.06 (-2.76%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.10
$2.19
50-Day Range
$2.10
$3.06
52-Week Range
$2.03
$19.65
Volume
10,698 shs
Average Volume
25,777 shs
Market Capitalization
$3.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BiondVax Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of BiondVax Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.30) to ($0.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars


BVXV stock logo

About BiondVax Pharmaceuticals (NASDAQ:BVXV) Stock

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
BiondVax to Present at BIO-Europe Spring
BiondVax Presenting at BIO CEO & Investor Conference
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
BiondVax to Present at Biotech Showcase 2023
BiondVax CEO Issues Letter to Shareholders
BiondVax Regains Nasdaq Compliance
See More Headlines
Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Company Calendar

Last Earnings
3/28/2022
Today
3/27/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BVXV
Employees
15
Year Founded
N/A

Profitability

Net Income
$-12,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.23 per share

Miscellaneous

Free Float
1,755,000
Market Cap
$3.95 million
Optionable
Not Optionable
Beta
2.49

Key Executives

  • Amir Reichman
    Chief Executive Officer & Director
  • Elad Mark
    Chief Operating Officer
  • Uri Ben-Or
    Chief Financial Officer
  • Tamar Ben-Yedidia
    Chief Science Officer
  • Dalit Weinstein Fischer
    Head-Technical, Research & Development













BVXV Stock - Frequently Asked Questions

How have BVXV shares performed in 2023?

BiondVax Pharmaceuticals' stock was trading at $2.96 on January 1st, 2023. Since then, BVXV shares have decreased by 28.7% and is now trading at $2.11.
View the best growth stocks for 2023 here
.

When is BiondVax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our BVXV earnings forecast
.

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced its quarterly earnings data on Monday, March, 28th. The company reported ($2.70) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $1.80.

When did BiondVax Pharmaceuticals' stock split?

Shares of BiondVax Pharmaceuticals reverse split before market open on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $2.11.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $3.95 million. The company earns $-12,850,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531.

This page (NASDAQ:BVXV) was last updated on 3/28/2023 by MarketBeat.com Staff